Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Oita University | OTHER |
| Japan International Cooperation Agency | OTHER |
| JDWNRH | OTHER |
| Khesar Gyalpo University of Medical Sciences of Bhutan |
Not provided
Not provided
Not provided
Background: Helicobacter pylori is a major risk factor for gastric cancer, yet in many developing countries, including Bhutan where gastric cancer incidence is high, access to screening and eradication is limited. The investigators conducted the first large-scale, population-based survey of H. pylori infection and gastric disease in Bhutan to provide baseline data before the launch of a national gastric cancer prevention program.
Methods: Permanent residents aged ≥12 years from 24 villages under Dawakha Basic Health Unit II catchment area were enrolled (December 2019-March 2023). H. pylori status was determined by serum IgG testing, gastric atrophy by serum pepsinogen, and endoscopy was offered to high-risk groups.
The investigators enrolled permanent residents aged ≥12 years living in communities within the catchment area of Dawakha BHU II, Paro District, Bhutan, between December 2019 and March 2023. The objectives of this study were to evaluate the status of H. pylori infection, the prevalence of endoscopic gastric diseases including gastric cancer and peptic ulcers, and to provide eradication therapy for infected individuals. Exclusion criteria included individuals with medical conditions in which triple therapy or endoscopy was contraindicated (e.g., pregnancy, renal disease, history of respiratory difficulty), those with a prior history of H. pylori eradication therapy, and individuals who declined to provide informed consent.
The study protocol complied with the ethical principles of the Declaration of Helsinki and was approved by the Institutional Review Board of Khesar Gyalpo University of Medical Sciences of Bhutan (approval number: PO/2019/076). Written informed consent was obtained from all participants. This prospective clinical trial was registered on July 1, 2021, in the University Hospital Medical Information Network (UMIN), under the identifier UMIN000044707 (http://www.umin.ac.jp/ctr/index.htm).
All participants underwent H. pylori serological testing and measurement of serum pepsinogen levels to assess infection status and evaluate the degree of serological gastric atrophy, respectively.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| H pylori positive individual | Experimental | H pylori positive individual receiving triple therapy |
|
| H. pylori positive individuals for UBT test | Experimental | The H pylori positive individuals are treated by triple therapy. After 6-8 weeks, the eradication is confirmed by using the UBT (13C Urea Breath Test: Beijing Richen-force Science & Technology Co. Ltd). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rabeprazole Sodium, Amoxicillin Hydrate, Clarithromycin | Drug | 7 days therapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of H. pylori | The seroprevalence of H. pylori (IgG ≥10 U/m) as positive for the H pylori | 2 months |
| Gastric atrophy by pepsinogen test | As a marker of gastric atrophy, serum levels of pepsinogen I and II were measured using a chemiluminescence enzyme immunoassay (E-Plate Eiken Disc Pepsinogen I and II; Eiken Chemical Co., Ltd., Tochigi, Japan). A positive result in the pepsinogen method was defined as a pepsinogen I level ≤70 ng/mL and a pepsinogen I/II ratio ≤3. Based on the results of both the pepsinogen test and H. pylori IgG levels, participants were classified into four ABC groups (A-D), which reflect the risk of gastric cancer according to the ABC method. | 2 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Gastrointestinal endoscopic examination | Based on the results of the serological tests, upper gastrointestinal endoscopy was performed in participants classified as ABC group, C or D( as high risk of gastric cancer group), as well as those classified as group B who were over 40 years of age. In addition, endoscopy was also conducted for individuals who voluntarily requested the procedure, regardless of their ABC classification. |
Not provided
Inclusion Criteria:
• Both male and female age 12 years and above in the selected communities for H. pylori infection screening
Exclusion Criteria:
Exclusion criteria for screening
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yumiko Kamogawa, M.D., Ph.D. | NPO HIGAN | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Khesar Gyalpo University of Medical Sciences of Bhutan | Thimphu | Thimphu District | Bhutan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| UNKNOWN |
| Royal Centre for Disease Control Bhutan | UNKNOWN |
Screening of H pylori and eradication in order to prevent gastric cancer using community-based longitudinal study
Not provided
Not provided
Not provided
Not provided
| Upper gastrointestinal endoscopy for the H. pylori and serum pepsinogen positive individuals (high risk group of gastric cancer) | Diagnostic Test | Endoscopic examinations were conducted using a GIF-150 endoscope in combination with the CV150 system (Olympus Co., Tokyo, Japan). |
|
| Urea Breath Test for the prevalence of H pylori | Device | After eradication of the H pylori with drug success of the therapy was assessed 6 to 8 weeks after treatment using the UBT(C13 Urea Breath Test: Beijing Richen-Force Science & Techinology Co. Ltd.) |
|
| 3 months |
| H pylori eradication therapy | Patients diagnosed with H. pylori infection received a standard 7-day triple therapy regimen consisting of rabeprazole (10 mg twice daily), amoxicillin (750 mg twice daily), and clarithromycin (200 mg twice daily) as the first-line treatment. Medication adherence was confirmed through daily individual telephone calls with each participant. | 3 months |
| Urea Breath Test (UBT) of H pylori eradication therapy | Success of the H pylori eradication was assessed 6 to 8 weeks after treatment using the urea breath test. | 8 weeks |
| ID | Term |
|---|---|
| D013274 | Stomach Neoplasms |
| ID | Term |
|---|---|
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D013272 | Stomach Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D064750 | Rabeprazole |
| D017291 | Clarithromycin |
| D016145 | Endoscopy, Digestive System |
| ID | Term |
|---|---|
| D053799 | 2-Pyridinylmethylsulfinylbenzimidazoles |
| D013454 | Sulfoxides |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D004917 | Erythromycin |
| D018942 | Macrolides |
| D061065 | Polyketides |
| D007783 | Lactones |
| D003938 | Diagnostic Techniques, Digestive System |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D004724 | Endoscopy |
| D003949 | Diagnostic Techniques, Surgical |
| D013505 | Digestive System Surgical Procedures |
| D013514 | Surgical Procedures, Operative |
| D019060 | Minimally Invasive Surgical Procedures |
Not provided
Not provided